Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Praveen Tyle"'
Autor:
Thomas L. Hunt, LuAnn Bundrant, Alan Wilson, Kenneth Kassler-Taub, Chris Warner, Phil Banks, Praveen Tyle, Suma Gopinathan, Suman Wason, Kristi A. Boehm
Publikováno v:
Clinical therapeutics. 43(6)
Purpose For neuropathic pain, current therapies do not provide relief for most patients; less than half achieve a 50% pain reduction. Current analgesics have adverse effects. We present 2 Phase I studies of LX9211, a new small-molecule AP2-associated
Publikováno v:
Archives of Physical Medicine and Rehabilitation. 97:e91
Publikováno v:
Pharmaceutical Development and Technology. 4:623-632
The object of this investigation was to perform detailed solid-state characterization studies on the different solid forms of AG337 and to determine the conditions of their interconversions. Solid-state characterization was done using differential sc
Publikováno v:
Journal of Pharmaceutical Sciences. 87:886-890
The purpose of this study was to determine the intestinal absorption characteristics of AG337, a mechanism-based inhibitor of thymidylate synthase, using a perfused rat intestinal model. Effects of site, pH, temperature, concentration, Na+, and inhib
Publikováno v:
International Journal of Pharmaceutics. 167:49-56
AG2034 is an anticancer drug designed using protein structure-based techniques. As demonstrated in preformulation studies [ Wang et al., 1997 . Preformulation studies of a novel glycinamide ribonucleotide formyl transferase inhibitor, AG2034 (in prep
Autor:
Praveen Tyle, Alekha K. Dash
Publikováno v:
Journal of Pharmaceutical Sciences. 85:1123-1127
AG337 (Thymitaq) is an antitumor compound synthesized by Agouron Pharmaceuticals, Inc., using protein structure-based drug design. AG337 is a hydrochloride salt with a molecular formula of C14H12N4OS·2HCl. This compound was subjected to thermal anal
Publikováno v:
Drug Development and Industrial Pharmacy. 22:603-608
AG337 is a novel thymidylate synthase inhibitor possessing potent antitumorogenic activity which was designed using protein structure-based techniques. It is currently undergoing clinical trials as both N and oral formulations. Based on AG337's short
Publikováno v:
Drug Development and Industrial Pharmacy. 21:1773-1780
The stability of AG337, a selective thymidylate synthase inhibitor, in 5% Dextrose in Water (D5W) PVC infusion bags and sodium bicarbonate treated D5W infusion bags was studied at 30°C for seven days. AG337 Solution for Injection, 2% was diluted in
Publikováno v:
International Journal of Pharmaceutics. 105:227-233
A topical anhydrous semisolid was developed for a novel chemical entity to maximize delivery of drug in the target organ, the skin. Excipients were selected based on increasing concentration of drug into the skin and the ability to form semisolids. U
Publikováno v:
International Journal of Pharmaceutics. 103:187-197
AG-85, a lipophilic drug synthesized by rational drug design, is inhibitory to cellular growth in vitro by inhibition of the enzyme thymidylate synthase which catalyses the rate-limiting step in the de novo synthesis of thymidine nucleotides (Appelt